Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL).
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2015
At a glance
- Drugs Alemtuzumab (Primary) ; Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 13 Jun 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database.
- 25 Jul 2011 New trial record